Strategies for the management of multi-drug resistant tuberculosis in Kampala, Uganda. (360G-Wellcome-063410_B_00_Z)
Multidrug resistant tuberculosis (MDR-TB) is emerging as a serious threat to control of TB globally. Most MDR-TB occurs in developing countries that cannot afford treatment regimens and infection control measures that appear to be effective in the U.S. and Europe. Investigators at New Jersey Medical School, the London School of Hygiene and Tropical Medicine and Makerere University and their collaborators propose to develop cost-effective affordable strategies for the management of individual patients and prevention of nosocomial transmission. Novel approaches will be taken to monitor infectiousness of cases and activity of drugs and for the rapid diagnosis of drug resistance. Inexpensive administrative and environmental controls will be taken to reduce transmission of drug resistant disease. The Scientific aims of this proposal are: To determine the prevalence of primary and secondary drug resistance in TB patients treated in the National TB and Leprosy Control Programme (NTLP) at Mulago Hospital. To determine the extent of nosocomial transmission of drug resistant TB on the TB Ward at Mulago Hospital and to identify predictive host and microbial factors that predict transmission. To evaluate new interventions applied on an individual basis to reduce nosocomial transmission of drug resistant TB: Rapid diagnostics; Novel microbiologic and immunologic approaches to monitor therapy; Modified lower cost third line treatment regimens. To evaluate the impact of administrative and environmental controls as well as new treatment regimens on the extent of nosocomial transmission of drug resistant TB: Segregation of new and retreatment cases; Assessment and modification of airflow; New treatment regimens.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2001-10-01T00:00:00+00:00 |
| Internal ID | 063410/B/00/Z |
| Planned Dates: End Date | 2007-12-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2001-12-01T00:00:00+00:00 |
| Amount Awarded | 506867 |
| Financial Year | 2001/02 |
| Lead Applicant | Prof Roy Mugerwa |
| Grant Programme: Title | Programme Grant |
| Partnership Name | Burroughs Wellcome Collaboration |
| Applicant Surname | Mugerwa |
| Approval Committee | WT-BWF Infectious Diseases Initiative |
| Other Applicant(s) | Dr Thomas Aisu, Dr Alphonse Okwera, Dr Francis Adatu |
| Recipient Org: Country | Uganda |
| Recipient Org: City | Kampala |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | Yes |
| Total amount including partnership funding | 506867 |